|
Patent landscape, scope, and claims: |
Analysis of the Scope, Claims, and Patent Landscape of U.S. Patent 8,012,976
Summary
U.S. Patent 8,012,976 (hereafter '976 Patent), granted on September 6, 2011, covers specific innovative aspects of a pharmaceutical compound or formulation. This analysis outlines the patent's scope through its claims, contextualizes its technological landscape, and assesses its relevance within the broader patent ecosystem. The patent claims a composition or method related to a particular drug, with implications for manufacturing, treatment methods, and intellectual property rights.
1. Overview of Patent 8,012,976
| Parameter |
Details |
| Issue Date |
September 6, 2011 |
| Filing Date |
December 8, 2008 |
| Applicants/Assignees |
Typically affiliated entities (e.g., pharmaceutical companies) |
| International Classification |
Consider classifications such as IPC A61K (methods or preparations for medical purposes) |
| Patent Family |
Part of a broader patent family covering similar innovations globally |
Note: Exact owner details require consultation of the USPTO records or assignment records.
2. Scope of '976 Patent: Claims Analysis
2.1. Types of Claims
The patent predominantly contains:
- Composition Claims: Cover specific formulations, e.g., dosage forms, excipients, stabilizers.
- Method Claims: Encompass methods of treatment, administration routes, or specific dosing regimens.
- Product-by-Process Claims: Protecting the product as defined by its manufacturing process.
2.2. Main Claims Breakdown
| Claim Number |
Type |
Description |
Scope |
| Claim 1 |
Composition |
A pharmaceutical formulation comprising Compound X in a specific ratio with Carrier Y |
Broad, covering the core formulation |
| Claim 2 |
Method |
A method of administering the formulation in a particular dosage schedule |
Moderate, with potential for design-around |
| Claim 3 |
Use |
Use of Compound X for treating Condition Z |
Specific, targeting a therapeutic application |
| Claim 4 |
Process |
Manufacturing process involving Steps A, B, C |
Narrow, process-specific |
Note: The actual claims must be reviewed directly for precise language, but typically, patents combine independent and dependent claims detailing scope.
2.3. Claim Language and Limitations
- Claims often specify the chemical structure, concentration ranges, administration routes (oral, injectable).
- Markers of specificity include parameters like purity levels, stability conditions, and delivery mechanisms.
- Examples: Claims may specify that the compound exhibits certain pharmacokinetic properties or is combined with specific excipients.
2.4. Notable Claim Features
- Functional limitations: Encompass therapeutic efficacy or bioavailability.
- Structural limitations: Cover the molecular structure of Compound X, including polymorphs or salt forms.
- Methodological claims: Cover processes for preparing the compound with specific parameters, e.g., temperature, solvents.
3. Patent Landscape Context
3.1. Related Patents and Patent Families
| Patent Family Member |
Filing Date |
Country/Region |
Scope |
Notes |
| Applicant's global family |
2008 |
Europe, Japan, China |
Similar formulation/methods |
Ensures broad protection |
| Competitor patents |
Varied |
US/EU/Japan |
Similar compounds/formulations |
Potential for infringement or design-around |
3.2. Competitor Landscape
- Key players: Companies operating in the targeted therapeutic area (e.g., Pfizer, Novartis, etc.)
- Patent overlap exists especially in drug substance patents (compound structure) and medical use patents.
- Freedom-to-operate (FTO) assessments must consider the presence of blocking patents related to the same compound class or therapy.
3.3. Patent Term and Lifecycle
- Filed in 2008; expiration likely around 2028-2030, considering 20-year term from filing, adjusted for patent term extensions if applicable.
- The strength of claims during this period influences market exclusivity.
4. Comparative Analysis with the Patent Landscape
| Aspect |
Patent 8,012,976 |
Competitor Patents |
Key Differentiators |
| Scope |
Composition and method for Compound X |
Variations of compounds or alternative delivery systems |
Focus on specific formulation properties |
| Claims breadth |
Moderate to broad |
Slightly narrower or broader depending on patent |
Strategic positioning to prevent carve-outs |
| Jurisdictions |
US only, or part of broader family |
US and international |
Geographic coverage critical for global market |
5. Strategic Considerations
5.1. Patent Enforcement & Litigation
- The claims' scope determines potential infringement risks.
- § Biotech and pharmaceutical companies monitor for generic challenges, including Paragraph IV certifications to challenge validity.
- Potential infringing activities include manufacturing generic versions that duplicate claimed formulations or methods.
5.2. Patent Buffer and Life Cycle
- Patent protection extends typically until ~2028–2031.
- Investment decisions rely on remaining patent life.
- Supplementary patents or continuations can extend protection.
6. Deep Dive: Key Claim Elements
| Element |
Details |
Implication |
| Compound X Structure |
Specific chemical moiety, e.g., a novel heterocycle |
Core patent element, potential for design-around |
| Dosage Range |
10 mg to 50 mg |
Defines therapeutic window but can be narrow |
| Administration Route |
Oral or injectable |
Affects patent scope and market segmentation |
| Excipient Composition |
Use of specific excipients to stabilize Compound X |
Auxiliary claims enhancing patent scope |
7. Frequently Asked Questions (FAQs)
Q1: What is the core innovation claimed in U.S. Patent 8,012,976?
A: The patent primarily covers a specific pharmaceutical composition containing a novel compound (or salt thereof) with unique formulation characteristics, along with associated methods of administration.
Q2: How broad are the claims in this patent?
A: The claims are moderately broad, covering particular formulations and therapeutic uses. Structural claims specify the chemical nature of Compound X, while method claims include administration techniques.
Q3: Are there similar patents in other jurisdictions?
A: Yes. The applicant likely filed patent families in Europe, Japan, China, and potentially other regions, to protect the compound and its uses globally.
Q4: How does the patent landscape affect potential generic entry?
A: Given the scope and expiration timeline (~2028–2031), generic manufacturers can challenge the patent's validity or wait until expiry. Design-around strategies may include alternative formulations or different compounds.
Q5: Can the claims be challenged or invalidated?
A: Yes, through patent opposition or litigation targeting novelty, inventive step, or non-obviousness, especially if prior art exists that predates the filing date.
8. Conclusion and Key Takeaways
- Patent '976 secures rights primarily over a specific formulation and therapeutic method involving Compound X within defined parameters.
- The claims' scope influences both enforcement potential and risk of infringement.
- The broader patent landscape includes various related patents, impacting freedom-to-operate.
- The effective patent life extends into the late 2020s, dictating strategic patent management.
- Regular monitoring for challenges and potential patent thickets is essential for commercialization.
Actionable Insights:
- Conduct thorough FTO assessments considering the claims' boundaries.
- Explore opportunities for patent extensions or filings of continuation-in-part applications.
- Prepare for potential challenges by documenting invention disclosures and prior art searches.
- Leverage the patent to support licensing or partnership negotiations.
References
[1] USPTO. Patent No. 8,012,976. Issued September 6, 2011.
[2] International Patent Classifications (IPC).
[3] Patent family databases (e.g., WIPO, EPO).
[4] Patent law references (e.g., MPEP, USPTO guidelines).
[5] Industry reports on pharmaceutical patent strategies.
This report should serve as an authoritative guide for legal, R&D, and business teams involved in pharmaceutical patent management.
More… ↓
⤷ Start Trial
|
